Stockscreener 앱 받기
2.16
4.35%
0.09
Grace Therapeutics Inc 주식(GRCE)의 최신 뉴스
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics, Inc. (NASDAQ: GRCE) Share Price, GRCE Stock News, GRCE Share Price & Updates - Kalkine
Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Form 8K Grace Therapeutics, Inc For: 13 August By Investing.com - Investing.com Nigeria
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise - Stock Titan
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock Titan
Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE - TradingView
Grace Therapeutics Raises Capital to Advance GTx-104 Program - TipRanks
Grace Therapeutics Raises $10 Million in Private Placement, Grants Registration Rights - TradingView
Grace Therapeutics announces securities purchase agreement for $10M private placement - ROI-NJ
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
GRCE Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Grace Therapeutics Secures $10M Private Placement Agreement - Intellectia AI
Grace Therapeutics, Inc. announced that it has received $9.999998 million in funding - marketscreener.com
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
Grace Therapeutics raises $10 million in private placement By Investing.com - Investing.com Australia
Grace Therapeutics raises $10 million in private placement - Investing.com
Grace Therapeutics raises $10M in private place... - pluang.com
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - quiverquant.com
Grace Therapeutics Announces $10 Million Private Placement - Moomoo
Grace Therapeutics prices USD 10 million private placement at USD 2.1 per share - Bitget
Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.com
GRCE Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Grace Therapeutics Receives Type a Meeting Minutes from FDA and Provides Update on GTx-104 Clinical-Stage Injectable Formulation - marketscreener.com
Grace Therapeutics (GRCE) FDA Meeting Highlights Manufacturing Compliance Focus, Market Implies High Growth - GuruFocus
Grace Therapeutics receives FDA meeting minutes on GTx-104 - Investing.com
Grace Therapeutics advances dual-source manufacturing for GTx-104 - TipRanks
Grace receives FDA Type A meeting minutes; advances dual-source manufacturing toward NDA resubmission - TradingView
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration - The Manila Times
Grace Therapeutics receives FDA meeting minutes on GTx-104 By Investing.com - Investing.com Canada
Grace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmission - Quiver Quantitative
Grace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104 - Stock Titan
Grace Therapeutics, Inc (GRCE) Institutional Confidence - TradingKey
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
Grace Therapeutics, Inc (GRCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Grace Therapeutics, Inc (GRCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Grace Therapeutics, Inc (GRCE) Cash Flow - TradingKey
Price to sales forward of Grace Therapeutics, Inc. – FWB:L8S - TradingView
GRCE|Grace Therapeutics, Inc|Price:2.330|Chg%:-0.020 - TradingKey
Price to earnings forward of Grace Therapeutics, Inc. – FWB:L8S - TradingView
Grace Therapeutics Inc. (GRCE) Q2 2026 Earnings: Significant EPS Beat Driven by Cost DisciplineROIC Trend Report - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therape - The National Law Review
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating - Moomoo
Grace Therapeutics (GRCE) Faces Mild Pressure Near Key SupportBreakaway Gap - dars.gov.et
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
Enterprise value to revenue forward of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Price to book forward of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Enterprise value to EBITDA forward of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Price to earnings forward of Grace Therapeutics, Inc. – LS:A40LEL - TradingView
Price to sales forward of Grace Therapeutics, Inc. – LS:A40LEL - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - AOL.com
Grace Therapeutics Q2 2026 Earnings: Narrower Net Loss Beats ConsensusEarnings Power Value - dars.gov.et
0.52%
0.07%
자본화:
|
볼륨(24시간):